Cwm LLC Has $46.77 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

Cwm LLC boosted its position in Amgen Inc. (NASDAQ:AMGN) by 8.0% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 150,112 shares of the medical research company’s stock after purchasing an additional 11,175 shares during the period. Cwm LLC’s holdings in Amgen were worth $46,768,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Greatmark Investment Partners Inc. lifted its position in Amgen by 2.6% during the first quarter. Greatmark Investment Partners Inc. now owns 70,637 shares of the medical research company’s stock worth $22,007,000 after acquiring an additional 1,821 shares during the last quarter. TFR Capital LLC. acquired a new stake in Amgen during the first quarter worth approximately $227,000. Hughes Financial Services LLC acquired a new stake in Amgen during the first quarter worth approximately $95,000. Oxbow Advisors LLC lifted its position in Amgen by 868.3% during the first quarter. Oxbow Advisors LLC now owns 10,932 shares of the medical research company’s stock worth $3,406,000 after acquiring an additional 9,803 shares during the last quarter. Finally, Schear Investment Advisers LLC lifted its position in Amgen by 3.2% during the first quarter. Schear Investment Advisers LLC now owns 5,646 shares of the medical research company’s stock worth $1,759,000 after acquiring an additional 173 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AMGN has been the subject of several research reports. Guggenheim initiated coverage on shares of Amgen in a research report on Tuesday, May 20th. They set a “neutral” rating and a $288.00 price objective for the company. Piper Sandler reiterated an “overweight” rating and issued a $328.00 price target on shares of Amgen in a research report on Friday, June 27th. UBS Group reiterated a “neutral” rating and issued a $315.00 price target (down from $319.00) on shares of Amgen in a research report on Friday, May 2nd. Cantor Fitzgerald reiterated a “neutral” rating and issued a $305.00 price target on shares of Amgen in a research report on Tuesday, June 24th. Finally, Mizuho lifted their price target on shares of Amgen from $235.00 to $280.00 and gave the company a “neutral” rating in a research report on Wednesday, May 7th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $307.82.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the business’s stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total transaction of $434,520.00. Following the sale, the senior vice president owned 8,162 shares of the company’s stock, valued at approximately $2,364,368.16. The trade was a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.76% of the company’s stock.

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $295.27 on Friday. The company’s 50 day simple moving average is $283.56 and its 200 day simple moving average is $288.13. The stock has a market capitalization of $158.77 billion, a price-to-earnings ratio of 26.94, a price-to-earnings-growth ratio of 2.67 and a beta of 0.49. The company has a debt-to-equity ratio of 8.70, a current ratio of 1.17 and a quick ratio of 0.88. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.18 by $0.72. The business had revenue of $8.15 billion for the quarter, compared to analysts’ expectations of $8.05 billion. Amgen had a net margin of 17.39% and a return on equity of 176.11%. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period last year, the firm posted $3.96 earnings per share. As a group, research analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.